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ABSTRACT
Objectives: We aimed to investigate potential associations between human leukocyte antigen
(HLA) class I and class II alleles and the development of anaphylactic/anaphylactoid reactions
in patients with multiple sclerosis (MS) treated with natalizumab.
Methods: HLA class I and II genotyping was performed in patients with MS who experienced
anaphylactic/anaphylactoid reactions and in patients who did not develop infusion-related allergic
reactions following natalizumab administration.
Results: A total of 119 patients with MS from 3 different cohorts were included in the study: 54 with
natalizumab-related anaphylactic/anaphylactoid reactions and 65 without allergic reactions.
HLA-DRB1*13 and HLA-DRB1*14 alleles were significantly increased in patients who developed ana-
phylactic/anaphylactoid reactions (pM-H 5 33 1027; odds ratio [OR]M-H 5 8.96, 95% confidence inter-
val [CI] 5 3.40–23.64), with a positive predictive value (PPV) of 82%. In contrast, the HLA-DRB1*15
allele was significantly more represented in patients who did not develop anaphylactic/anaphylactoid
reactions to natalizumab (pM-H 5 63 1024; ORM-H 5 0.2, 95%CI5 0.08–0.50), with a PPV of 81%.
Conclusions: HLA-DRB1 genotyping before natalizumab treatment may help neurologists to iden-
tify patients with MS at risk for developing serious systemic hypersensitivity reactions associated
with natalizumab administration. Neurol Neuroimmunol Neuroinflamm 2014;1:e47; doi: 10.1212/
NXI.0000000000000047
GLOSSARY
CI 5 confidence interval; HLA 5 human leukocyte antigen; MS 5 multiple sclerosis; NPV 5 negative predictive value; OR 5
odds ratio; PPV 5 positive predictive value.
Similar to other biological agents, natalizumab, a highly effective therapy for multiple sclerosis
(MS), can induce infusion-related hypersensitivity reactions. These reactions typically occur
within 2 hours after infusion, with a peak at the second infusion, and range from urticaria, aller-
gic dermatitis, and hives to more serious anaphylactic/anaphylactoid reactions in which treat-
ment should be discontinued.1 The incidence of systemic hypersensitivity reactions classified
as anaphylactoid or anaphylactic was reported to be 0.8% in the AFFIRM trial2 and ranged
between 1.0% and 3.8% in more recent observational studies.3–6
An important number of drug hypersensitivity reactions are known to be mediated through
interactions with human leukocyte antigen (HLA) molecules encoded within the major
histocompatibility complex.7 Based on this, in the present study we investigated whether the
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development of anaphylactic/anaphylactoid
reactions in patients with MS treated with na-
talizumab was associated with particular HLA
class I and class II alleles.
METHODS Patients and HLA typing. Inclusion criteria
were patients with MS treated with natalizumab who developed
anaphylactic/anaphylactoid reactions within 2 hours after infu-
sion between the second and eleventh administrations of natalizu-
mab, which motivated natalizumab suspension. Patients fulfilled
the clinical criteria for the diagnosis of anaphylaxis promulgated
in the World Allergy Organization anaphylaxis guidelines.8 Pa-
tients with MS who did not develop anaphylactic/anaphylactoid
reactions during natalizumab infusions were used as controls.
Genomic DNA was extracted from peripheral blood samples
using standard methods. HLA genotyping was performed bymeans
of the PCR-SSOP Luminex method using Lifecodes HLA-A,
HLA-B, HLA-DRB1, and HLA-DQB typing kits (Immucor
Gamma Transplant Diagnostics, Inc., Heppignies,- Belgium) ac-
cording to the manufacturer’s instructions.
Statistical analysis. Statistical analysis was performed by using the
SPSS 17.0 package (SPSS Inc., Chicago, IL). Comparisons of groups
were analyzed using the x2 test of a Fisher exact test (when expected
values were below 5). To calculate combined odds ratios (ORs) and
95% confidence intervals (CIs), we used the Cochran-Mantel-
Haenszel method implemented in Review Manager RevMan v. 5.0
(The Nordic Cochrane Centre, Copenhagen, Denmark). p values
,0.05 were considered statistically significant. The Der Simonian
and Laird random effects model was used according to the results of
the tests of heterogeneity. A sensitivity analysis was performed to test
the relative influence of each study on the results. Studies were
sequentially dropped, and the effect on the change in the overall
degree of heterogeneity was determined.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the corresponding local
ethics committees, and all patients gave their informed consent.
RESULTS A total of 119 patients withMS belonging to
3 different cohorts (French, n 5 63; Spanish, n 5 48;
German, n5 8) were included in the study. A summary
of demographic and main clinical characteristics of pa-
tients with MS who participated in the study is shown in
table 1. Information on anti-natalizumab antibodies was
available for 27 (50%) of the 54 patients with MS who
developed infusion-related anaphylactic/anaphylactoid
reactions, and 22 patients (81.5%) were positive for
anti-natalizumab antibodies.
Tables e-1, e-2, and e-3 summarize the distribu-
tion of HLA alleles in all the patients with MS
included in the study. The frequency of carriers of
the HLA-DRB1*13 and HLA-DRB1*14 alleles (the
latter in almost complete linkage disequilibrium with
HLA-DQB1*05:03) was significantly increased in pa-
tients who experienced anaphylactoid reactions com-
pared to patients who did not develop drug-related
allergic reactions (28/54 [52.0%] vs 6/65 [10.5%];
pM-H 5 3 3 1027; ORM-H [95% CI]5 8.96 [3.40–
23.64]) (figure). In contrast, as depicted in the figure,
the frequency of carriers of the HLA-DRB1*15 allele
(in almost complete linkage disequilibrium with
HLA-DQB1*06:02) was significantly increased in
the group of patients without allergic reactions to
natalizumab compared to patients who developed
anaphylactoid reactions (7/54 [13.0%] vs 29/65
[44.8%]; pM-H 5 6 3 1024; ORM-H [95% CI] 5
0.2 [0.08–0.50]). In the European population, the
frequencies of the HLA-DRB1*15 and HLA-
DRB1*13/*14 alleles are 14% each.
Most probably these risk and protective HLA class
II alleles conformed ancestral haplotypes with class I
alleles, since the HLA-DRB1*13 and HLA-DRB1*14
alleles were frequently accompanied by HLA-A*24,
and theHLA-DRB1*15 allele byHLA-A*03 orHLA-
B*07 (see tables e-2 and e-3). Nonetheless, the HLA
class II alleles remained the best associated markers of
Table 1 Summary of demographic and baseline clinical characteristics of patients with MS treated with
natalizumab included in the study
Characteristics
France Spain Germany
AR No AR AR No AR AR No AR
N 33 30 16 32 5 3
Age, ya 35.8 (6.3) 37.5 (9.0) 35.8 (8.3) 38.1 (7.1) 33.4 (4.8) 37.7 (8.7)
Female/male (% women) 30/3 (90.9) 21/9 (70.0) 12/4 (75.0) 23/9 (71.9) 4/1 (80.0) 2/1 (66.7)
Duration of disease, ya 8.9 (7.0) 10.2 (6.2) 8.7 (2.6) 11.7 (6.7) 7.8 (3.2) 6.7 (4.5)
EDSS scoreb 3.1 (1.5–4.0) 3.8 (3.0–5.0) 3.3 (2.0–4.4) 3.3 (2.0–4.0) 2.0 (1.5–2.5) 2.5 (2.0–3.0)
No. of relapsesc 2.0 (1.0) 2.2 (1.0) 1.7 (0.9) 1.5 (1.0) 4.5 (0.7) 2.5 (2.1)
Abbreviations: AR 5 anaphylactic/anaphylactoid reaction; EDSS 5 Expanded Disability Status Scale; MS 5 multiple
sclerosis.
Data are expressed as mean (SD) unless otherwise stated.
aRefers to age and disease duration at treatment onset.
bData are expressed as mean (interquartile range).
c Refers to the number of relapses in the year before treatment onset. For the Germany cohort, information on relapses and
EDSS is missing in 5 and 3 patients, respectively.
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anaphylactic/anaphylactoid reactions to natalizumab,
conferring the following positive and negative predic-
tive values (PPV/NPV): PPV 5 0.82/NPV 5 0.69
for the HLA-DRB1*13 and *14, and PPV 5 0.81/
NPV 5 0.57 for the HLA-DRB1*15.
DISCUSSION Two types of infusion-related
hypersensitivity reactions have been described in
patients with MS treated with natalizumab: type I
allergic reactions, which usually occur within 2 hours
after infusion,1 and type III hypersensitivity reactions,
which typically develop during several days.9 Type I
hypersensitivity reactions include serious systemic
anaphylactic/anaphylactoid, with an incidence that has
been reported to be near 4% in some observational
studies.3,6 When these hypersensitivity reactions
are present, administration of natalizumab must be
discontinued and patients should not be retreated.
Aiming to identify patients at risk for developing
anaphylactic/anaphylactoid reactions to natalizumab,
we performed HLA typing for class I and class II
alleles in patients with MS from 3 different cohorts
who were treated with natalizumab. The selection
of the HLA region as the main target for genotyping
was based on current evidence in the literature dem-
onstrating significant associations between HLA and
predisposition to adverse drug reactions.7 Drug
hypersensitivity reactions are supposed to be medi-
ated by inappropriate T-cell activation, and the key
proteins implicated in these responses are the HLA
molecules. Several models have been proposed to
explain the mechanisms whereby small synthetic
compounds are recognized by T cells in an HLA-
dependent manner, including the hapten/prohapten
model, the altered peptide repertoire model, and the
p-i model (pharmacologic interaction of drugs with
immune receptors).10 Examples of drug-induced
hypersensitivity reactions influenced by the HLA
are the reactions to the reverse-transcriptase inhibitor
abacavir and the xanthine oxidase inhibitor allopuri-
nol, which are mediated by HLA class I alleles, and
the reactions to the reverse-transcriptase inhibitor
Figure Meta-analysis showing the influence of HLA-DRB1*13/*14 and HLA-DRB1*15 in the development of anaphylactic/anaphylactoid
reactions to natalizumab in the different study cohorts
Meta-analysis showing the influence of HLA-DRB1*13/*14 (A) and HLA-DRB1*15 (B) in the development of anaphylactic/anaphylactoid reactions to
natalizumab in the different study cohorts. Forest plots showing the overall data and data after eliminating heterogeneity by removing the Spanish cohort.
CI 5 confidence interval; HLA 5 human leukocyte antigen; HN1/HN2 5 patients who developed and did not develop anaphylactic/anaphylactoid reactions,
respectively; M–H 5 Mantel-Haenszel.
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nevirapine and the first-line anticonvulsant carbam-
azepine, which are mediated by both HLA class I and
class II alleles.7,10
Patients with MS carrying HLA-DRB1*13 and
HLA-DRB1*14 alleles were at higher risk for devel-
oping natalizumab-related anaphylactic/anaphylac-
toid reactions compared to patients without allergic
reactions, with an OR of 9 and a PPV of 82%. On the
other hand, the HLA-DRB1*15 allele, which is
known to be the main genetic risk for MS, had a
protective effect on the development of anaphylac-
tic/anaphylactoid reactions, with an OR of 0.2 and
a PPV of 81%.
Neutralizing antibodies against natalizumab are
usually present in patients having type I hypersensitiv-
ity reactions.11 In our study, 81% of the patients with
MS who experienced anaphylactic/anaphylactoid reac-
tions were positive for anti-natalizumab antibodies.
Based on these results, genotyping for theHLA-DRB1
gene may be incorporated into clinical practice before
initiating treatment with natalizumab to identify
MS patients with increased (or decreased) risk for
developing serious hypersensitivity reactions following
IV administration of natalizumab. We suggest that
patients with MS and HLA-DRB1*13 and HLA-
DRB1*14 alleles be strictly monitored during natali-
zumab administration, maintaining a high index of
suspicion for hypersensitivity reactions.
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